By Rob Curran

Shares of Biocryst Pharmaceuticals rose premarket after the biotech firm eked out a profit for the first quarter thanks to demand for a rare-disease product, and said it expected to turn a profit for 2025.

In the first quarter, BioCryst swung to a profit of $32,000, or less than a penny a share from a loss of $35.4 million, or 17 cents a share, a year earlier.

Revenue surged 57% to $145.5 million, thanks to robust demand for its Oraldeyo product. Oraldeyo is a treatment for rare disease hereditary angioedema, which manifests itself as swelling.

Shares of BioCryst on Monday rose 16% to $10.35, premarket.

Demand for Oraldeyo is running ahead of expectations. BioCryst boosted its projection for net revenue from the product to a range between $580 million and $600 million from a prior estimate of $535 million to $550 million.

As a result, BioCryst now expects to be profitable in 2025, a year ahead of its prior estimates.

Oraldeyo is already approved for use in sufferers over the age of 12 in many countries. Biocryst said it submitted a new drug application to the U.S. Food and Drug Administration for use in children aged 2 to 11 in oral form. Biocryst expects to apply for commercial approval of the oral form in Europe and other global markets later this year.

Biocryst said it expects data from an early stage trial of a treatment for another rare disease, Netherton syndrome, later this year.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 05, 2025 07:51 ET (11:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.